Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study
Authors:
- Wasim HanifWHWasim Hanif
- Waqar MalikWMWaqar Malik
- Ali KamalAKAli Kamal
- Parnia GeransarPGParnia Geransar
- Nicola ListerNLNicola Lister
- Chris AndrewsCAChris Andrews
- Anthony BarnettABAnthony Barnett
- 12 May 2011
- journal article
- research article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 27 (7) , 1367-1374
Abstract
Objective:To compare the incidence of hypoglycaemic events (HEs) in a real-world setting in Muslim patients with type 2 diabetes mellitus fasting during Ramadan.Research design and methods:We performed a ≤16-week prospective, non-interventional, two-cohort study. Data were collected 1–6 weeks before and ≤6 weeks after fasting. Patients were enrolled who had been receiving vildagliptin (50 mg twice daily) or sulphonylurea (SU) as add-on to metformin at least 4 weeks prior to fasting.Main outcome measures:The primary efficacy endpoint was incidence of HEs during the Ramadan fast. Changes in glycated haemoglobin (HbA1c) and body weight, as well as adherence to treatment, were also assessed.Results:Seventy-two patients were enrolled (vildagliptin, n = 30; SU, n = 41; no treatment, n = 1), of whom 23 (76.7%) and 36 (87.8%), respectively, completed the study. With vildagliptin, there were no HEs or severe HEs, compared with 34 HEs (15 patients, 41.7%) and one severe (grade 2) HE with SU. The mean betwee...Keywords
This publication has 24 references indexed in Scilit:
- Diabetes and Ramadan: How to Achieve a Safer Fast for Muslims with DiabetesBritish Journal of Diabetes, 2010
- Recommendations for Management of Diabetes During RamadanDiabetes Care, 2010
- Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year studyDiabetes, Obesity and Metabolism, 2010
- Management of people with diabetes wanting to fast during RamadanBMJ, 2010
- Ramadan Education and Awareness in Diabetes (READ) programme for Muslims with Type 2 diabetes who fast during RamadanDiabetic Medicine, 2010
- Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during RamadanInternational Journal Of Clinical Practice, 2009
- Fifty‐two‐week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapyDiabetes, Obesity and Metabolism, 2008
- Detection of impaired glucose tolerance and undiagnosed type 2 diabetes in UK South Asians: an effective screening strategyDiabetes, Obesity and Metabolism, 2008
- Recommendations for Management of Diabetes During RamadanDiabetes Care, 2005
- A Population-Based Study of Diabetes and Its Characteristics During the Fasting Month of Ramadan in 13 CountriesDiabetes Care, 2004